



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Himmelsbach et al.) Art Unit: 1624
Serial No. : 09/934,753) Examiner: Coleman, B.L.
Confirmation No. : 8721
Filed : August 22, 2001
For : AMINOQUINAZOLINES WHICH INHIBIT SIGNAL
TRANSDUCTION MEDIATED BY TYROSINE KINASES
Docket No. : 5/1301

1624
118
RECEIVED

MAR 28 2003

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents
Washington, DC 20231
on March 17, 2003.

Susan K. Pocchiarri
By: Susan K. Pocchiarri
Reg. No. 45,016

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office action mailed on December 17, 2002, please enter the following amendments and reconsider the application in view of these amendments and the following remarks.

It is hereby petitioned that the period permitted for response be extended by 2 months, pursuant to 37 CFR 1.136(a), so that it will expire on March 17, 2003. The requisite fee is provided by the enclosed Fee Transmittal.

ELECTION

Restriction to one of the following inventions has been required under 35 USC 121:

- I. Claims 1-7, drawn to compounds, compositions and method of use of the compounds of formula I where X is nitrogen, classified in class 544, subclass 293 and class 514, subclass 266.2.

03/27/2003 CUD111 00000117 022955 09934753
01 FC:1252 410.00 CH


II. Claims 1 and 5-7, drawn to compounds, compositions and method of use of the compounds of formula I where X is a methyne group, classified in class 546, subclass 159 and 160 and class 514, subclass 313.

Applicants hereby elect to prosecute claims directed to the invention of Group I. The election is made without traverse.

Tentative election of a single species within the elected group has been further required.

Applicants hereby elect as a single disclosed species the compound of Example I (2) (at page 23 of the instant specification):

4-[(R)-(1-phenylethyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)amino]-quinazoline having the following structure:



Respectfully submitted,

Susan K. Pocchiari
Attorney for Applicant(s)
Reg. No. 45,016

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4868